{"filings":[{"id":1085276,"accession_number":"0001104659-26-074619","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2026-06-16T20:43:51+00:00","items":["1.01","2.01","2.04","3.01","3.03","5.01","5.02","5.03","8.01","9.01"],"status":"ready","headline":"Assertio completes Zydus merger at $23.50/share; notes conversion set at $382.58 per $1,000","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Merger completed June 16; shareholders receive $23.50 per share cash; stock delisted from Nasdaq.","66.32% of shares tendered; all conditions satisfied; company now wholly owned by Zydus Lifesciences.","Board replaced: Ravi Yadavar and Punit Patel named directors; prior directors and officers resigned.","Holders of $40M 6.5% convertible notes due 2027 can elect repurchase at 100% plus accrued interest by July 16, or convert into $382.58 cash per $1,000 principal.","First Supplemental Indenture executed; conversion rate adjusted to cash-only based on $23.50 merger consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":484036,"accession_number":"0001104659-26-063064","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2026-05-18T13:23:36+00:00","items":["8.01"],"status":"ready","headline":"Assertio to be acquired by Zydus Worldwide for $23.50 per share in cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Zydus Worldwide DMCC will acquire Assertio via tender offer at $23.50/share cash, followed by a merger.","Tender offer commences May 18, 2026; closing subject to tender of majority of shares and regulatory approvals.","Parent waived requirement for Assertio to commence a Note Offer for its 6.50% Convertible Senior Notes due 2027.","Convertible Note holders will gain repurchase and conversion rights upon the fundamental change triggered by the merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":51043,"accession_number":"0001104659-26-059856","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2026-05-13T13:03:35+00:00","items":["1.01","1.02","7.01","9.01"],"status":"ready","headline":"Assertio to be acquired by Zydus for $23.50/share cash; terminates prior Garda deal","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["All-cash tender offer of $23.50/share (~$166.4M total) by Zydus subsidiary.","75.8% premium to unaffected price (Mar 20, 2026); 30.6% above original Garda deal.","Prior Garda agreement terminated; Garda paid $5.81M termination fee funded by Zydus.","No financing contingency; guaranteed by Zydus entity; closing expected Q2 2026.","Company to launch tender offer for $40M 6.50% Convertible Notes due 2027 concurrently."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95644,"accession_number":"0001104659-26-057577","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2026-05-08T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Assertio and Garda delay tender offer launch to May 14, 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Mutual agreement to extend deadline to commence tender offer for all outstanding shares to May 14, 2026.","Acquisition price remains $21.80 per share cash, total consideration $153.2 million.","Tender offer for Convertible Senior Notes also delayed to May 14, 2026.","Company expects to file Schedule 14D-9 on May 14, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95643,"accession_number":"0001104659-26-057258","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Assertio shareholders approve 400,000-share increase in 2014 Omnibus Incentive Plan","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2014 Omnibus Incentive Plan to increase available shares by 400,000 (total 2,271,167).","All six director nominees elected; votes for ranged from 1,748,914 to 1,783,789.","Advisory vote on executive compensation passed with 1,739,652 for vs 451,308 against.","Ratification of Grant Thornton as auditor for FY2026 approved with 3,577,437 for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95642,"accession_number":"0001104659-26-055320","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2026-05-05T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Assertio and Garda postpone tender offer commencement to May 8, 2026","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Tender offer to acquire all outstanding ASRT shares for $21.80/share ($153.2M total) postponed from May 4 to May 8.","Amended merger agreement entered May 1, 2026; Schedule 14D-9 to be filed May 8.","Tender offer for outstanding Convertible Senior Notes also postponed to May 8.","Both parties mutually agreed to the extension; no change to per-share consideration."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95641,"accession_number":"0001104659-26-054488","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Assertio increases acquisition price to $21.80/share all cash; Garda's revised offer up 21.1%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Offer price $21.80/share in cash, no CVR, up from $18 plus CVR (21.1% premium to original offer).","Premium of 63.1% to unaffected stock price on March 20, 2026; total equity value ~$153.2M.","Board unanimously approved; tender offer to commence by May 4, 2026; closing expected Q2 2026.","Financing commitments fully committed: $22.2M equity (Limber and Lund) and up to $130M debt (Colbeck).","Company withdraws 2026 guidance and cancels Q1 2026 earnings conference call due to pending transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95640,"accession_number":"0001104659-26-051692","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2026-04-29T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Assertio-Garda extend tender offer deadline to May 4, 2026; $125.1M deal","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Mutual agreement extends tender offer commencement deadline to May 4, 2026.","Deal price: $18.00/share cash, total equity value of $125.1M, plus a contingent value right.","20-day window-shop provision allows Assertio to seek superior proposals; reduced breakup fee applies.","Merger agreement dated April 8, 2026; no change in terms announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95639,"accession_number":"0001104659-26-046147","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Assertio: Garda to launch tender offer April 29 at $18.00/share ($125M cash)","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Garda intends to commence tender offer on April 29, 2026 to purchase all outstanding Assertio shares.","Offer: $18.00 per share cash, total $125.1 million, plus a contingent value right.","Tender offer begins the day after the 20-day window-shop period ends on April 28.","Assertio may solicit superior proposals during window-shop; reduced breakup fee applies if terminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95638,"accession_number":"0001104659-26-043227","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Assertio completes sale of six product franchises to Cosette for $35M cash plus up to $35M contingent payments","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Products sold: INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, OTREXUP; deal closed April 8, 2026.","Upfront cash $35M; potential milestones up to $32M (SYMPAZAN, INDOCIN, OTREXUP) and SPRIX earn-out (quality approval $1M, 8% gross profits through 2027, $2M if 2027 net sales >$7M).","Pro forma continuing ops: 2025 net loss ~$31.3M (historical $30.4M); 2024 net loss ~$27.5M (historical $21.6M).","Estimated transaction costs ~$1.9M; estimated gain on disposal ~$16M.","Company also divested Assertio Therapeutics in May 2025; results removed from continuing ops in pro forma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95637,"accession_number":"0001104659-26-041236","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2026-04-09T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Assertio to be acquired by Garda for $18/share plus CVR; sells assets to Cosette for $35M","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Garda Therapeutics to acquire Assertio via cash tender offer at $18.00 per share plus one CVR per share.","Concurrently, Assertio sells its INDOCIN, SPRIX, and other product franchises to Cosette for $35M cash plus up to $35M in milestones.","Equity investors commit $17M and Colbeck provides $87M debt financing; no financing condition for the offer.","Closing conditions include minimum net cash of $115M; termination fee is $4.8M ($1.75M for qualified bidder).","Company to launch note offer for its $40M 6.50% Convertible Notes due 2027 contingent on merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":95636,"accession_number":"0001104659-26-041569","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K/A","filed_at":"2026-04-09T23:59:59+00:00","items":["1.01","5.02","7.01","9.01"],"status":"ready","headline":"Assertio to be acquired by Garda Therapeutics in $18.00/share cash tender offer plus CVRs","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition by Garda Therapeutics at $18.00/share cash plus one CVR per share; tender offer to commence within 10 business days.","Asset sale to Cosette Pharmaceuticals for $35M cash upfront plus up to $32M in milestone payments and SPRIX-related CVR payments.","Equity commitment of $17M from Joseph Limber and Brett Lund; debt commitment of $87M from Colbeck Capital Management.","Termination fee: $4.8M standard, reduced to $1.75M for a Qualified Bidder prior to Window Shop End Time.","CEO Mark Reisenauer's non-compete extended to 18 months post-termination in connection with the merger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":1.0,"calibrated_materiality_score":1.0,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108844,"accession_number":"0001808665-26-000010","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assertio reports Q4 adjusted EBITDA loss of $4.1M; Rolvedon sales drop to $0.4M from $15.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Rolvedon Q4 net sales $0.4M vs $15.4M YoY; sell-in in Q3 2025 covered two quarters of demand, sales under new label expected Q2 2026.","Sympazan net sales grew to $3.1M from $2.5M; Indocin flat at $5.5M.","Gross margin improved to 75% from 61% on product mix and inventory write-downs in prior year.","Adjusted EBITDA loss $4.1M vs income $3.4M last year; cash dropped to $63.4M from $93.4M in Q3.","FY2026 guidance: net product sales $110M-$125M, Adj EBITDA $28M-$40M; CEO prioritizes Rolvedon and disciplined oncology build."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108843,"accession_number":"0001104659-26-002899","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Assertio regains Nasdaq minimum bid price compliance; matter closed","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Assertio on Jan 12, 2026 of compliance with minimum bid price rule 5550(a)(2).","Company's common stock (ASRT) remains listed on Nasdaq Capital Market; compliance matter is closed.","Resolution eliminates delisting risk and allows continued trading on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125303,"accession_number":"0001104659-25-123772","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2025-12-22T23:59:59+00:00","items":["3.03","5.03","9.01"],"status":"ready","headline":"Assertio Holdings to effect 1:15 reverse stock split effective Dec 26, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at ratio 1:15 effective 12:01 a.m. ET on Dec 26, 2025.","Common stock will trade split-adjusted under symbol ASRT with new CUSIP 04546C 304.","No fractional shares; cash will be paid for fractional interests based on Dec 24 closing price.","Proportionate adjustments to conversion rate of 6.5% Convertible Senior Notes due 2027 and equity incentive plans.","Reverse split approved by stockholders at May 7, 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125302,"accession_number":"0001104659-25-115051","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2025-11-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Former CEO Brendan O'Grady resigns from Assertio board effective Nov 17, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brendan P. O'Grady executed a waiver and release agreement on November 17, 2025.","He resigned from the Board of Directors, effective as of the same date.","Resignation is pursuant to the Management Continuity Agreement previously filed on Form 10-Q.","No replacement director has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125301,"accession_number":"0001808665-25-000034","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Q3 Rolvedon sales $38.6M (+157% YoY); guides FY25 rev $110-112M; promotes Schwichtenberg President/COO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Rolvedon net sales $38.6M vs $15.0M YoY; large distributor purchases pulled forward two quarters of demand.","Adjusted EBITDA $20.9M vs $4.4M YoY; gross margin 72% vs 74% due to product mix shift to Rolvedon.","FY2025 net product sales guidance narrowed to $110-112M; adjusted EBITDA guidance $14-16M.","Paul Schwichtenberg promoted to President and COO effective Nov 3, 2025 from Chief Transformation Officer.","Cash, equivalents and short-term investments $93.4M as of Sept 30; temporary decline expected then increase in Q2 2026."],"consensus_eps_estimate":-1.3005,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":105171000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125300,"accession_number":"0001104659-25-104439","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2025-10-30T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Assertio appoints Mark Reisenauer as CEO, replacing Brendan O'Grady","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Brendan O'Grady separated effective Oct 27, 2025; entitled to severance under his existing agreement.","Board appoints director Mark Reisenauer as CEO; receives $800k base salary, 85% target bonus (no 2025 bonus), and initial equity grants (1M options + 500k RSUs).","Reisenauer has 30+ years experience, previously President of U.S. Commercial at Astellas (~$5B sales).","Company to report Q3 2025 results on Nov 10, 2025; expects to update guidance within current range at that time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125299,"accession_number":"0001104659-25-098758","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2025-10-10T23:59:59+00:00","items":["1.01"],"status":"ready","headline":"Assertio, Hanmi amend ROLVEDON supply agreement; price cut mid-single digits","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mid-single-digit price reduction on ROLVEDON drug substance from Hanmi, fixed through license term.","Supplier may request price increases from 2028 if costs rise above threshold.","Per-gram pricing decreases if global ROLVEDON volume exceeds unmet threshold.","Spectrum must provide annual forecast; at least 50% of forecasted orders binding.","No minimum purchase requirements; Spectrum may negotiate lower price if process cuts costs."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142020,"accession_number":"0001808665-25-000024","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assertio Q2 net product sales $28.8M, net loss $16.4M, cash rises to $98.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP net loss $16.4M ($0.17 per share) vs $3.7M loss ($0.04) in prior year Q2.","Adjusted EBITDA $5.6M, up from $3.1M; adjusted EPS $0.02 vs $0.01.","Rolvedon sales $16.1M (+$1M YoY); Sympazan $3.2M (+$0.5M); Indocin $3.0M (down from $6.9M due to generic competition).","Cash & investments $98.2M, up from $87.3M at Q1 2025; company narrows guidance.","SG&A $17.0M, down from $18.4M, includes $2.4M employee retention tax credit benefit."],"consensus_eps_estimate":-1.1628,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":55712000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159986,"accession_number":"0001104659-25-047861","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Assertio stockholders approve reverse stock split authorization and increase in incentive plan shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to certificate of incorporation authorizing board to effect reverse stock split at ratio of 1-for-2 to 1-for-15, to be completed by May 7, 2026.","Stockholders approved amendment to 2014 Omnibus Incentive Plan to increase shares available by 8,200,000.","All seven director nominees elected: Heather L. Mason, Sravan K. Emany, Sigurd C. Kirk, William T. McKee, Brendan P. O'Grady, Mark L. Reisenauer, David M. Stark.","Advisory vote on executive compensation passed with 24,575,700 for, 6,671,868 against.","Ratification of Grant Thornton LLP as independent auditor for fiscal year 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159985,"accession_number":"0001808665-25-000011","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assertio Q1 net product sales $26.0M (-18% YoY), GAAP loss $13.5M; settles DOJ qui tam, transfers opioid liabilities","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $26.0M vs $31.9M YoY; GAAP net loss $13.5M ($0.14 loss per share) vs $4.5M loss.","Adjusted EBITDA $0.2M vs $7.4M YoY; adjusted EPS ($0.04) vs $0.04 positive.","Rolvedon net sales $13.1M (-10% YoY) on lower pricing; Indocin $5.5M (-37% YoY) on generic competition.","Settled DOJ False Claims Act lawsuit and last Glumetza antitrust action; transferred subsidiary with opioid liabilities.","Cash $87.3M; $40M in 6.5% convertible notes due 2027; no near-term maturities."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":26488000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178312,"accession_number":"0001808665-25-000006","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2025-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assertio Reports Fourth Quarter and Full Year 2024 Financial Results","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2024 net product sales were $29.6 million, up from $28.7 million in Q3 2024.","Full year 2024 net product sales totaled $120.8 million; Rolvedon sales exceeded $60.0 million.","Full year 2024 cash flow from operations was $26.4 million; cash and investments at year-end $100.1 million.","2025 guidance: net product sales $108M-$123M, adjusted EBITDA $10M-$19M.","CEO noted stabilization in 2024 and focus on Rolvedon growth and acquisition strategy for 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178311,"accession_number":"0001104659-25-006756","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2025-01-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Assertio receives Nasdaq deficiency notice for bid price below $1.00 per share","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stock closed below $1 for 32 consecutive business days; Nasdaq issued notice on Jan. 22, 2025.","Company has 180 calendar days (until July 21, 2025) to regain compliance.","Compliance requires bid price at $1 or more for at least 10 consecutive business days.","If not compliant by July 21, may seek an additional 180-day extension if eligible.","Company will monitor and may consider options, but no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194972,"accession_number":"0001104659-24-129417","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2024-12-17T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Assertio appoints Schwichtenberg as CTO, Pietryga as CCO, Reisenauer to board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul Schwichtenberg (formerly CCO, CFO) named Chief Transformation Officer effective Dec 16, 2024, focusing on growth and new revenue strategies.","Mary Pietryga appointed Chief Commercial Officer effective Dec 16, 2024, overseeing sales, marketing, and access.","Mark Reisenauer, former President US Commercial at Astellas, appointed to board effective Jan 2, 2025, also joining Compensation Committee.","Pietryga joins from Teva Pharmaceuticals as VP and Head of Global Biosimilar Portfolio."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194971,"accession_number":"0001808665-24-000041","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Assertio Q3 net sales $28.7M, adj EBITDA $5.3M; board adds Stark, loses Staple/Vacirca","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 net product sales $28.7M vs $35.1M YoY; net loss $2.9M vs $279.5M loss (prior year impairment).","Rolvedon net sales $15.0M (stable vs $15.1M Q2); Indocin $5.7M (down from $6.9M Q2) on generic competition.","Adjusted EBITDA $5.3M (down from $12.9M YoY); adjusted EPS $0.03 vs $0.01 YoY.","Cash and short-term investments $88.6M; debt $40M (6.5% convertible notes, maturity 2027).","Board changes: Staple/Vacirca departed Nov 7; Mason appointed Chair; Stark (ex-Teva CLO) named independent director."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":92778000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211266,"accession_number":"0001808665-24-000033","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assertio Q2 net product sales $30.7M, GAAP net loss $3.7M; reiterates FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $30.7M vs $40.1M in Q2 2023; GAAP net loss $0.04/share vs income $0.13/share.","Rolvedon net sales $15.1M, up from $14.5M QoQ; Indocin $6.9M, down from $8.7M due to generic competition.","Adjusted EBITDA $5.0M vs $24.8M in Q2 2023; cash from operations $7.4M.","Cash & short-term investments $88.4M, up from $80.7M; debt $40.0M in 6.5% convertible notes due 2027.","FY 2024 guidance reaffirmed: net product sales $110-125M, adjusted EBITDA $20-30M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":63574000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229823,"accession_number":"0001104659-24-066682","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2024-05-30T23:59:59+00:00","items":["5.02","5.03","5.07","9.01"],"status":"ready","headline":"Assertio shareholders reelect directors, approve incentive plan increase; two charter amendments fail","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved amendment to 2014 Omnibus Incentive Plan, adding 3,390,000 shares for issuance.","Proposal to amend certificate to provide officer exculpation under Delaware law did not pass (37.7M for, 6.1M against, short of majority of outstanding shares).","Proposal to eliminate pass-through voting provision for subsidiary Therapeutics also failed (41.4M for, 2.3M against, not a majority of outstanding shares).","All six director nominees elected with between 38.5M and 41.0M votes for each.","Bylaws amended effective May 30, 2024 to clarify stock ownership requirements for calling special meetings."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229822,"accession_number":"0001104659-24-065886","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2024-05-29T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Assertio appoints Brendan P. O'Grady as new CEO effective May 29, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brendan P. O'Grady appointed CEO and director, effective May 29, 2024.","Heather Mason transitions back to independent director role after serving as interim CEO since Jan 2024.","O'Grady base salary $850,000 with 85% target bonus; receives 1.8M stock options and 500K RSUs as inducement.","O'Grady previously CEO of Glenmark Global Formulations, CCO of Amwell, and CEO of Teva USA.","Management continuity agreement provides severance of 2x base salary plus target bonus upon change-in-control termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229821,"accession_number":"0001808665-24-000021","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assertio Q1 net product sales $31.9M; Rolvedon sales grow to $14.5M; guides FY $110-125M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales of $31.9M in Q1 2024 vs $41.8M in Q1 2023; net loss of $4.5M vs $3.5M loss.","Rolvedon net sales $14.5M, up from $11.0M in Q4 2023, driven by volume growth; same-day dosing trial enrollment completed, data expected year-end.","Indocin net sales $8.7M, down from $10.8M in Q4 2023 due to generic competition.","Adjusted EBITDA (non-GAAP) $7.4M in Q1 2024, up from $4.5M in Q4 2023; SG&A reduced to $18.5M from $24.0M.","FY 2024 guidance reaffirmed: net product sales $110-125M, adjusted EBITDA $20-30M; cash increased to $80.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":32448000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229820,"accession_number":"0001104659-24-042608","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Assertio director Tyree declines reelection over board retirement policy dispute","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James L. Tyree, Compensation Committee Chair, will not stand for reelection at 2024 annual meeting.","Tyree disagreed with potential waiver of mandatory retirement policy for Board Chair Peter D. Staple.","Board declined to act on Tyree's suggestion to raise retirement age from 72 to 75.","Company provided Tyree opportunity to respond; Exhibit 17.1 includes his correspondence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248302,"accession_number":"0001104659-24-039390","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2024-03-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Assertio regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on March 26, 2024 confirming regained compliance.","Minimum bid price requirement under Listing Rule 5550(a)(2) satisfied.","Matter is closed; no further action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248297,"accession_number":"0001104659-24-033520","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K/A","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assertio files 8-K/A to furnish Q4 2023 earnings call transcript; no new financial data","summary_kind":"llm","event_type":"earnings","confidence":"low","bullets":["Amendment filed to furnish transcript of March 11, 2024 earnings call; original 8-K delayed due to vendor technical issues.","No changes to previously reported Q4 and full year 2023 financial results; transcript provided as Exhibit 99.2.","Call covered Rolvedon sales growth, generic competition for Indocin, and ongoing CEO search; no specific numbers in this filing.","Forward-looking statements and non-GAAP measures discussed; no updated guidance or material events."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248301,"accession_number":"0001808665-24-000011","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Assertio reports Q4 2023 net product sales $32.5M, net loss $57.4M; guides 2024 sales $110-125M, adj. EBITDA $20-30M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 net product sales $32.5M (down 35% YoY); net loss $57.4M vs. income $88.6M in Q4 2022.","Full year 2023 net product sales $149.5M (down 3.6% YoY); net loss $331.9M vs. income $109.6M.","Non-GAAP adj. EBITDA Q4 $4.5M (down from $33.4M); adj. EPS $0.11 (vs. $0.32).","2024 guidance: net product sales $110-125M, adj. EBITDA $20-30M; Rolvedon sales target >$100M in coming years.","Board appointed Sigurd Kirk, former Allergan EVP Business Development, effective April 3, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248300,"accession_number":"0001104659-24-027093","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2024-02-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Assertio Holdings receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Feb 21, 2024, because common stock bid price closed below $1.00 for 30 consecutive business days.","Has 180 calendar days (until Aug 19, 2024) to regain compliance by closing at $1.00+ for 10 consecutive business days.","If not compliant by deadline, may be eligible for additional 180-day period; company may consider reverse stock split.","No immediate delisting; the Notice does not affect current trading on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248299,"accession_number":"0001104659-24-007316","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2024-01-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Former CEO Daniel A. Peisert resigns from Assertio Holdings Board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Daniel A. Peisert, former President and CEO, executed a waiver and release on Jan 24, 2024.","Peisert resigned as a member of the Board effective immediately upon execution.","Waiver and release agreement substantially follows form filed as Exhibit 10.2 to 2021 10-K.","No replacement for Board seat announced in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":248298,"accession_number":"0001104659-24-001870","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2024-01-05T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Assertio Holdings CEO Daniel Peisert departs; board member Heather Mason named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Daniel Peisert separated effective Jan 2, 2024; entitled to severance under management continuity agreement.","Heather Mason appointed Interim CEO; base salary $540k/yr, bonus up to $200k, stock option for 550,000 shares.","Board committee changes: Peter Staple to Audit, Sravan Emany to Compensation, William McKee chairs Nominating & Governance.","Permanent CEO search initiated; Mason's term capped at six months unless extended by agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265794,"accession_number":"0001104659-23-117706","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2023-11-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Assertio appoints Sravan Emany to Board of Directors, effective Nov 14.","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Board expanded from 6 to 7 members; Emany fills new vacancy created by increase.","Emany is CFO of Ironwood Pharmaceuticals, with prior roles at Integra LifeSciences and Bank of America.","Appointed to Audit Committee; receives standard non-employee director compensation and indemnification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265793,"accession_number":"0001808665-23-000062","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2023-11-08T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Assertio posts Q3 net loss of $279.5M; names Ajay Patel CFO, Schwichtenberg to commercial role","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 GAAP net loss $279.5M ($3.42 EPS); adjusted EPS $0.01; includes $238.8M impairment charge.","Net product sales $35.1M, up 2% YoY; Rolvedon contributed $7.1M for two months post-acquisition.","Indocin net sales $17.9M, down $4M YoY due to generic competition; SG&A rose to $21.0M.","Adjusted EBITDA $12.9M, down from $21.4M; cash $76.9M; convertible debt $40M.","Ajay Patel appointed CFO (adds to CAO role); Paul Schwichtenberg moves to SVP commercial."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":119084000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":265792,"accession_number":"0001104659-23-108277","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K/A","filed_at":"2023-10-10T23:59:59+00:00","items":["2.01","9.01"],"status":"ready","headline":"Assertio amends 8-K to eliminate requirement to file Spectrum acquisition financials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment removes earlier commitment to file financial statements and pro forma for Spectrum acquisition.","Company determined such disclosures are not required under Item 9.01 after further analysis.","Original 8-K filed July 31, 2023; this Amendment filed October 10, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283018,"accession_number":"0001808665-23-000049","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2023-08-03T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assertio Q2 sales up 13% to $40.1M; closes Spectrum buy; withdraws guidance on generic Indocin","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales $40.1M (+13% YoY); GAAP net income $8.5M ($0.13 EPS), adjusted EPS $0.19 vs $0.28 YoY.","Acquisition of Spectrum closed July 31; ROLVEDON Q2 sales $21.0M, launch trajectory strong.","Cash from operations $18.6M; cash and equivalents $70.2M at quarter end.","2023 financial guidance withdrawn after FDA approval of generic indomethacin suppository.","SG&A $16.8M, up from $10.5M, includes $3.4M transaction costs vs $2.0M insurance benefit last year."],"consensus_eps_estimate":null,"consensus_eps_actual":0.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":83457000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":283017,"accession_number":"0001104659-23-085942","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2023-08-01T23:59:59+00:00","items":["2.01","5.02","5.07","7.01","8.01","9.01"],"status":"ready","headline":"Assertio closes acquisition of Spectrum Pharmaceuticals; expects accretion in 2024","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition of Spectrum closed July 31, 2023; each Spectrum share converted into 0.1783 Assertio shares plus one CVR worth up to $0.20.","Jeffrey Vacirca, MD, FACP, appointed to Assertio's board as independent director effective at closing.","Transaction expected to be significantly accretive to Assertio's adjusted EPS and operating cash flow in 2024.","Stockholders of both companies approved the deal; updated guidance to be provided on August 3 Q2 earnings call.","Deal combines Assertio's digital sales with Spectrum's ROLVEDON commercial team to enhance market access."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302393,"accession_number":"0001104659-23-071175","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2023-06-14T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Assertio lowers stockholder meeting quorum to one-third of voting power","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board adopted amendment reducing quorum from majority to one-third of outstanding voting power.","Amendment effective immediately on June 12, 2023.","Change applies to all stockholder meetings for transaction of business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302392,"accession_number":"0001104659-23-060711","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2023-05-15T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve 4.15M share increase to 2014 Plan; fail to pass subsidiary charter amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved 4,150,000 share increase to 2014 Omnibus Incentive Plan (Proposal 2).","Proposal 5 to eliminate pass-through voting provision in subsidiary charter failed; did not receive majority of outstanding shares.","All five director nominees elected; say-on-pay approved with 'Every Year' frequency.","Grant Thornton LLP ratified as auditor for FY 2023.","The failed subsidiary amendment could impact corporate governance flexibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302391,"accession_number":"0001808665-23-000028","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assertio Q1 sales +18% to $41.8M; raises FY2023 outlook; plans Spectrum acquisition in Q3","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 net product sales $41.8M, up 18% YoY; GAAP net loss of $3.5M vs net income of $9.1M a year ago.","Adjusted EBITDA $25.6M vs $23.9M YoY; adjusted EPS $0.29 vs $0.38.","Full-year net product sales guidance raised to $157-167M; adjusted EBITDA guidance raised to $90-98M.","Acquisition of Spectrum (all-stock + CVR) expected to close Q3 2023, accretive to adjusted EPS and cash flow in 2024.","Converted $30M of convertible debt in Feb 2023, reducing outstanding debt by 43% and saving $2M annual interest."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":42466000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302390,"accession_number":"0001104659-23-049669","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2023-04-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Assertio to acquire Spectrum in all-stock plus contingent value rights deal","summary_kind":"llm","event_type":"m_and_a","confidence":"medium","bullets":["Assertio will acquire all outstanding Spectrum shares via all-stock and contingent value rights transaction.","Merger sub will merge into Spectrum; Spectrum will survive as a wholly owned subsidiary of Assertio.","Transaction requires stockholder and regulatory approvals; closing expected later in 2023.","Details of deal value and per-share consideration will be provided in the Form S-4 registration statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":302389,"accession_number":"0001104659-23-049365","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2023-04-25T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Assertio to acquire Spectrum Pharma in all-stock deal with CVRs, 0.1783 exchange ratio","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Each Spectrum share converts into 0.1783 Assertio shares plus one contingent value right (CVR).","CVRs offer up to $0.20/share total in two milestones: $175M net sales in 2024, $225M in 2025.","Termination fee of $8.3M payable by either party if deal terminated under certain conditions.","Merger expected to close by Oct 24, 2023, subject to stockholder approvals and antitrust clearance.","Spectrum will nominate one board member to Assertio's board effective at closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322050,"accession_number":"0001104659-23-031336","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2023-03-13T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Assertio Holdings confirms no deposits or accounts at Silicon Valley Bank","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company has zero deposits, funds, or securities at SVB; no active accounts.","Disclosure via 8-K on March 10, 2023 amid SVB collapse.","Reassures investors of no financial exposure to SVB failure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322049,"accession_number":"0001808665-23-000018","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2023-03-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Assertio Q4 net product sales $49.9M (+55% YoY); net income $88.6M; guides 2023 revenue $150-160M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net product sales Q4 $49.9M (+55% YoY); full year $155.1M (+42% YoY).","GAAP net income Q4 $88.6M (vs $4.6M) includes $80.4M tax benefit from valuation allowance reversal.","Adjusted EBITDA Q4 $33.4M (up from $17.8M); full year $101.6M (up from $48.8M).","2023 guidance: net product sales $150-160M, Adjusted EBITDA $85-93M; Q1 revenue $36-38M.","Feb 2023 debt exchange reduced debt 42.9%, saves $2M annual interest, accretive $0.02 to EPS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":322048,"accession_number":"0001104659-23-024510","cik":1808665,"company_name":"Assertio Holdings, Inc.","ticker":"ASRT","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Assertio exchanges $30M of 6.50% convertible notes for $10.5M cash + 7M shares; reduces debt by 42.9%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$30M principal of 6.50% Convertible Senior Notes due 2027 exchanged for $10.5M cash and ~7M shares.","Debt reduced by 42.9% from $70M to $40M remaining outstanding.","Annual interest savings of $2.0M from reduced debt.","Transaction accretive to diluted EPS by $0.02 in 2023.","Closing expected February 27, 2023; SVB Securities acted as exchange agent."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":151441190.5023494,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2023-02-23T23:59:59+00:00|322048"}